RxDoctor Payments Data

Lisa Teunissen, NP

Family · Grand Rapids, MINPI 1952966111

Payments from drug & device makers

$7,511in general payments, 2019–2025

Across 339 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$508
  • Merck$504
  • Takeda Pharmaceuticals U.S.A., Inc.$495
  • AstraZeneca$490
  • Incyte Corporation$472
  • Eisai Inc.$443
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,03594%
  • Education$4766%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis26$508
Merck19$504
Takeda Pharmaceuticals U.S.A., Inc.20$495
AstraZeneca(2 entities)25$490
Incyte Corporation21$472
Eisai Inc.20$443
Seagen Inc.11$385
Johnson & Johnson16$348
Pfizer18$320
Sanofi12$309
AbbVie11$238
Amgen10$228
Daiichi Sankyo Inc.9$198
E.r. Squibb & Sons, L.L.C.6$194
Jazz Pharmaceuticals Inc.8$168
Lilly USA, LLC8$151
Pharmacyclics LLC, An Abbvie Company7$148
GSK6$108
Bristol Myers Squibb6$106
Bayer4$88
Gilead(2 entities)4$82
Boehringer Ingelheim3$80
Beone Medicines USA, Inc.3$80
EMD Serono, Inc.5$76
AVEO Pharmaceuticals, Inc.2$75
Genmab U.S., Inc.3$73
Tersera Therapeutics LLC4$70
Genentech USA, Inc.4$69
Astellas Pharma US Inc3$63
Exelixis Inc.2$57
Sun Pharmaceutical Industries Inc.2$54
Geron Corporation2$54
Syndax Pharmaceuticals, Inc.3$52
Mirati Therapeutics, Inc.3$52
Taiho Oncology, Inc.2$42
G1 Therapeutics, Inc.2$40
Pharmacosmos Therapeutics Inc.2$40
Caris MPI, Inc.1$39
Regeneron Healthcare Solutions, Inc.1$36
Morphosys, US Inc.2$32
Blueprint Medicines Corporation1$30
ADC Therapeutics America, Inc.2$29
Beigene USA, Inc.1$28
Intera Oncology, Inc1$27
Ipsen Biopharmaceuticals, Inc1$26
Progenics Pharmaceuticals, Inc.1$25
Pharmaessentia USA Corporation1$25
Sumitomo Pharma America, Inc.1$23
Agios Pharmaceuticals, Inc.1$23
Alnylam Pharmaceuticals Inc.1$22
Springworks Therapeutics, Inc.1$20
Sobi, Inc1$18
Kyowa Kirin, Inc.1$17
Stemline Therapeutics Inc.1$17
Karyopharm Therapeutics Inc.1$17
Deciphera Pharmaceuticals Inc.1$16
Puma Biotechnology, Inc.1$15
Array Biopharma Inc1$14
Servier Pharmaceuticals LLC1$14
Acrotech Biopharma Inc.1$14

How this compares

$7,511 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$25,796
Medicare patients
68
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$7,260
Oxycodone Hcl14$234
Prochlorperazine Maleate13$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$320$7,26012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →